News & Blog

April 17, 2024 | Press Release
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease
April 16, 2024 | Press Release
Nobias Therapeutics Joins NVIDIA Inception Program for Startups
March 28, 2024 | Press Release
ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA
March 05, 2024 | Press Release
Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
February 14, 2024 | Press Release
ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
February 14, 2024 | Press Release
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
February 02, 2024 | Blog Post
2023 – A Year in Retrospect
January 31, 2024 | Blog Post
MEC in 4Q23: Pioneering the Future of Precision Medicine – More in 2024
January 18, 2024 | Press Release
Immunitas Therapeutics Appoints Annalisa D’Andrea, Ph.D., as Chief Scientific Officer
January 08, 2024 | Press Release
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend